<DOC>
	<DOC>NCT03025542</DOC>
	<brief_summary>This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis</brief_summary>
	<brief_title>Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male or female at least 18 years of age and less than or equal to 70 Chronic plaque psoriasis for at least 6 months prior to Screening Psoriasis Area and Severity Index (PASI) &gt;=12 and body surface area (BSA) &gt;=10% and Investigator's Global Assessment (IGA) score &gt;=3 on a 5point scale Candidates for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy Female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception up till 20 weeks after last administration of study drug, and have a negative pregnancy test at Visit 1 (Screening) and immediately prior to first dose Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active, up till 20 weeks after the last administration of study medication (anticipated 5 halflives) Subjects previously participating in a bimekizumab study Subjects with erythrodermic, guttate, pustular form of psoriasis, or druginduced psoriasis History of chronic or recurrent infections, or a serious or lifethreatening infection within the 6 months prior to the Baseline Visit (including herpes zoster) High risk of infection in the Investigator's opinion Current sign or symptom that may indicate an active infection Concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection Live (includes attenuated) vaccination within the 8 weeks prior to Baseline Subjects with concurrent malignancy or history of malignancy during the past 5 years (except for specific malignant condition as defined in the protocol) Primary immunosuppressive conditions TB infection, high risk of acquiring TB infection, latent TB infection (LTBI), or current or history of NTMB infection Laboratory abnormalities, as defined in the study protocol Any condition which, in the Investigator's judgement, would make the subject unsuitable for inclusion in the study Exposure to more than 1 biological response modifier (limited to antiTNF or IL12/23) or any biologic response modifier during the three months prior to the Baseline Visit Subjects have received previous treatment with any antiIL17 therapy for the treatment of psoriasis or psoriatic arthritis Subjects with a diagnosis of inflammatory conditions other than psoriasis or psoriatic arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, or systemic lupus erythematosus. Subjects with a diagnosis of Crohn's disease or ulcerative colitis are allowed as long as they have no active symptomatic disease at Screening or Baseline Subjects taking psoriatic arthritis medications other than nonsteroidal antiinflammatory drugs (NSAIDs) or analgesics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Chronic Plaque Psoriasis</keyword>
	<keyword>Bimekizumab</keyword>
</DOC>